Alzheimer’s
New treatments which can slow the progress of ´¡±ô³ú³ó±ð¾±³¾±ð°ù’s were given UK licences in 2024 but have not been recommended for ÐÇ¿ÕÊÓƵ use by the cost-effectiveness assessment body , a decision which will affect 70,000 patients in England.
The treatments were shown in trials to slow the rate of decline as a result of the early stages of ´¡±ô³ú³ó±ð¾±³¾±ð°ù’s by an average of about four to seven months.
You can read more about .
The US, Australia, Japan, Singapore, Taiwan, South Korea, China and several nations in the Middle East and South America have provided regulatory approval for one or both of these medicines.
Social media campaign assets
´¡±ô³ú³ó±ð¾±³¾±ð°ù’s
Last reviewed date: 23 June 2026
Next review date: 23 June 2029